argenx SE
ARGX
Jodie situation report
argenx SE's move is being confirmed by its market group.
No new filing conclusion is available. 8 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
- At least 9 of 13 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as BMRN begins moving with the group.
Invalidation: The live read weakens if participation falls to 4 of 13 members or fewer.
Who this business touches
The relationships behind ARGX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
VORVor Biopharma Inc.competitorMay 13, 2026 ▾
“Competition The autoimmune field is a competitive landscape involving multiple fusion protein class members (atacicept, povetacicept), monoclonal antibodies, other biologics, chimeric antigen receptor (CAR) T cells and small molecules either already marketed…”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ARGX is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.